FIELD: biotechnology.
SUBSTANCE: invention relates to a method of producing a population of cells which express a chimeric antigen receptor (CAR). Said method involves: (i) contacting the cell population with an agent which stimulates the CD3/TCR complex and/or an agent which stimulates a co-stimulating molecule on the surface of the cells; (ii) contacting a population of cells with a nucleic acid molecule encoding a CAR, thereby obtaining a population of cells containing a nucleic acid molecule, and (iii) collecting the cell population for storage or introduction, wherein step (ii) is carried out together with step (i) or not later than 20 hours after the beginning of step (i), and step (iii) is carried out not later than 30 hours after the beginning of step (i).
EFFECT: invention is effective for producing a population of cells which express a chimeric antigen receptor (CAR).
66 cl, 49 dwg, 26 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
